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OBJECTIVES: To compare patient adherence with chronic-use prescription medica-
tions between once- (QD) and twice-daily (BID) dosing. METHODS: Using a large 
claims database (MarketScan), prescription medications were deﬁ ned as QD if ≥80% 
of claims showed a quantity/day = 1 and were deﬁ ned as BID if ≥80% of claims had 
a quantity/day = 2. Data for patients (18 years or older) with the ﬁ rst claim in 2007 
were selected for analysis and were further limited to 4 classes of medications fre-
quently used by cardiovascular patients: antiplatelet, general cardiac, antihyperlipid-
emic, or antidiabetic medications. Adherence was measured by medication possession 
ratio (MPR) deﬁ ned as the number of days of medication supplied (between the ﬁ rst 
prescription ﬁ ll date and 365 days following)/365 days. a linear model (generalized 
estimating equation) accounting for within-patient correlations in patients using mul-
tiple medications was used to model the MPR. The model was stratiﬁ ed on medication 
class and adjusted for baseline confounding variables (gender, age, Charlson Comor-
bidity Index). RESULTS: A total of 1,077,936 patients were included, and the number 
of patient-medication combinations was 1,440,917 (QD: 1,384,565 and BID: 56,352). 
The mean MPR for BID compared to QD was −5% overall and −28% for antiplatelet 
agents, −19% for antihyperlipidemic agents, −7% for antidiabetic agents, and 3% for 
cardiac agents (P < 0.01 for all comparisons). CONCLUSIONS: This unique, recent, 
claims analysis, which investigated multiple therapeutic classes of medications in a 
large database, generally found lower adherence in BID dosing in medications fre-
quently used by cardiovascular patients; however, a wide range in the MPR differences 
between QD and BID dosing was observed between the therapeutic classes. Further 
research is needed to investigate the relationship between dosing complexity and 
therapeutic class of medications and subsequent patient adherence.
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OBJECTIVES: Switching of medications due to non-medical grounds may be a critical 
factor inﬂ uencing patients’ medication-based adherence (NA). The aim of this analysis 
is to examine the effects of medication switching on NA for hypertonic/diabetic (type 
II) patients. Only switches between medications containing the same active ingredient 
were examined. METHODS: Prescriptions ﬁ lled at 5 German pharmacies over a 
period of 2 years were analyzed. Patients who had ﬁ lled prescriptions for at least 3 
medications to control hypertonia (focus on Moxonidin—ATC-Code C02AC05) and/
or diabetes type 2 (focus on Metformin—ATC-Code A10BA02) were included. The 
NA was calculated using the medication possession ratio (MPR); NA was deﬁ ned as 
MPR < 80%. The average MPRs obtained while using the original and the discount 
products (before/after comparison) were compared using non-parametric tests for 
independent samples (Wilcoxon-Tests). RESULTS: Of the 344 hypertonia sufferers, 
253 received the active ingredient Moxonidin (NA patients’ percentage: 47.4%). In 
68 cases, a switch to the discount product took place (NA percentage before switch: 
46.4%). The percentage of NA patients was reduced to 39.1% after the switch. Of 
the 726 diabetic patients, 518 patients received Metformin (NA: 49.4%). a total of 
136 patients received a discount article after the discount contract was in place (NA 
before switch: 42.7%). After the switch, the NA percentage increased to 66.2%. 
CONCLUSIONS: In the case of hypertonia, medication switches had no signiﬁ cant 
effect on the NA. By contrast, switchers receiving Metformin exhibited a substantial 
increase in medication-based NA. In future, the focus of research in this area should 
be to discover whether speciﬁ c contracts concerning discount products (as, for 
example, in the case of Metformin) are related to particularly negative adherence 
effects and if so which factors inﬂ uence such effects.
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OBJECTIVES: Good adherence to long term management of chronic diseases such as 
hypertension is very vital in order to prevent long term mortality and morbidity. There 
are many factors associated with non-adherence to prescribed medications and one of 
it is lack ok knowledge and awareness among patients towards the disease they are 
suffering from. The aim of the present study is to evaluate the association between 
patient’s knowledge to hypertension disease state management and medication adher-
ence. METHODS: A cross-sectional study was undertaken with 385 established hyper-
tensive patients who visited out patient departments in two public hospitals of Quetta 
city, Pakistan. Besides the demographic and disease-related questions, two question-
naires (Hypertension Fact Questionnaire with 15 items for knowledge and Drug 
Attitude Inventory with 10 items) were used for data collection. Descriptive statistics 
and Spearman correlation were carried out by using SPSS version 16. RESULTS: Out 
of 385 patients (68.8% male; mean age: 39.02 ± 6.596), 236 (61.3%) of the patients 
had moderate degree of knowledge about hypertension. a total of 249 (64.7%) were 
categorized as poor adherent. Noticeably no patient was considered as good adherent 
in the study. Correlation coefﬁ cient between total score of knowledge and total adher-
ence was—0.170 (P < 0.001) indicating an inverse association between knowledge 
scores and adherence level. CONCLUSIONS: Patient knowledge about hypertension 
had weak relation with drug adherence in this cohort of study group. This is possibly 
due to the dominancy of other factors inﬂ uencing drug adherence such as perception 
of patients towards disease and drug, income, education, age etc in this cohort of 
study group. This calls attractive opportunities for further research on drug adherence 
and also identiﬁ es the gaps in providing optimum health care to patients.
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OBJECTIVES: To investigate the cost implication of unacceptable reﬁ ll-based adher-
ence rates of antihypertensive treatment in the South African private health care 
environment. METHODS: A non-experimental, retrospective drug utilization study 
was conducted on medicine claims data of a pharmacy beneﬁ t management company 
for hypertension patients for a four year period (January 1, 2005–December 31, 2008). 
The reﬁ ll-based adherence rate was calculated per trade name for all antihypertensive 
medicine items that were prescribed more than once to 171,815 patients. The follow-
ing equation was used: Reﬁ ll–adherence rate = (total number of days of antihyperten-
sive medicine items supplied—number of days supplied at last reﬁ ll)/(date last 
claimed—date ﬁ rst claimed). [RSA Rand (R)/$US = 6.38112 (2005); 6.78812 (2006); 
7.06926 (2007) and 8.27505 (2008)]. RESULTS: An average reﬁ ll-based adherence 
rate of 82.8% ± 125.9 was obtained for 376,954 antihypertensive medicine items. 
Approximately 54.5% of antihypertensive medicine items (n = 205,476) had accept-
able reﬁ ll-based adherence rates between 80% and 120%, 42.2% (n = 159153) had 
unacceptably low reﬁ ll-based adherence rates (less than 80%) and 3.3% (n = 12325) 
had unacceptably high rates (more than 120%). Those with unacceptably low or 
unacceptably high reﬁ ll-based adherence rates accounted for respectively 24.3% 
(R109,275,001) and 1.3% (R5 958,593.70) of the total cost (N = R448,883,473) of 
all antihypertensive medicine items (n = 376,954). The following pharmacological 
groups of antihypertensive drugs had on average unacceptable reﬁ ll-based adherence 
rates: diuretics (n = 114 623, 74.6% ± 131.7); central acting sympathetic nervous 
system inhibitors (n = 5 094; 79.9% ± 112.6); sympathetic nervous blockers (n = 3 
090; 76.3% ± 87.5). CONCLUSIONS: Since pharmacy records are generally comput-
erised, the prospect of using a simple algorithm to assess compliance based on reﬁ ll 
patterns is enticing, particularly for monitoring the progress of patients with chronic 
diseases.
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OBJECTIVES: Cardiovascular disease imposes a signiﬁ cant burden on patients and 
society, and is associated with considerable costs to the health care system. Although 
statins have been shown to reduce the risk of cardiovascular events, suboptimal adher-
ence and poor persistence with therapy remains a common problem. The need to lower 
health care costs has led to increased interest in policy-driven therapeutic substitution 
programs for statins, however their impact on patient adherence and persistence is 
often not considered. METHODS: A review of published literature describing the 
impact of policy-driven statin switch programs on adherence and persistence was 
conducted. PubMed search terms included: hydroxy-methyl-glutaryl-CoA Reductase 
Inhibitors (MESH), and statin, therapeutic, generic, substitute, switch, persistence, 
compliance, adherence (all ﬁ elds); the search was limited to articles published in 
English between 1989 to May 2010. Reference lists from selected papers were also 
reviewed. RESULTS: 4 studies were identiﬁ ed. Following therapeutic substitution of 
one statin for another, 20–25% of patients discontinued therapy within 6–12 months 
(4 studies). Additionally, one study found that patients were 20% more likely to 
discontinue treatment within the ﬁ rst year than those who did not switch. Further-
more, switching statins reduced adherence (i.e., probability of taking medication on 
most days) by 12–33% (3 studies). One study showed that switching statins for 
economic/ formulary reasons led to decreased ﬁ lling and utilization of statin prescrip-
tions overall. CONCLUSIONS: Low rates of adherence to statin therapy have been 
documented, despite strong evidence of clinical beneﬁ t with sustained use. As a result, 
many patients initiating statins may achieve limited clinical beneﬁ ts from therapy 
because of premature discontinuation. Policy-driven statin switch programs may 
further contribute to problems with persistence and adherence. While therapeutic 
substitution policies for statins may decrease drug plan costs, their impact on adher-
ence and persistence may signiﬁ cantly affect patient outcomes and increase costs to 
the health care system.
